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Abstract
Chronic pancreatitis is a chronic inflammatory disorder of the pancreas. The etiology is multi-fold, but all lead to progressive
scarring and loss of pancreatic function. Early diagnosis is difficult; and the understanding of the molecular events that
underlie this progressive disease is limited. In this study, we investigated differential proteins associated with mild and
severe chronic pancreatitis in comparison with normal pancreas and pancreatic cancer. Paraffin-embedded formalin-fixed
tissues from five well-characterized specimens each of normal pancreas (NL), mild chronic pancreatitis (MCP), severe chronic
pancreatitis (SCP) and pancreatic ductal adenocarcinoma (PDAC) were subjected to proteomic analysis using a ‘‘label-free’’
comparative approach. Our results show that the numbers of differential proteins increase substantially with the disease
severity, from mild to severe chronic pancreatitis, while the number of dysregulated proteins is highest in pancreatic
adenocarcinoma. Important functional groups and biological processes associated with chronic pancreatitis and cancer
include acinar cell secretory proteins, pancreatic fibrosis/stellate cell activation, glycoproteins, and inflammatory proteins.
Three differential proteins were selected for verification by immunohistochemistry, including collagen 14A1, lumican and
versican. Further canonical pathway analysis revealed that acute phase response signal, prothrombin activation pathway,
and pancreatic fibrosis/pancreatic stellate cell activation pathway were the most significant pathways involved in chronic
pancreatitis, while pathways relating to metabolism were the most significant pathways in pancreatic adenocarcinoma. Our
study reveals a group of differentially expressed proteins and the related pathways that may shed light on the pathogenesis
of chronic pancreatitis and the common molecular events associated with chronic pancreatitis and pancreatic
adenocarcinoma.
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Introduction
Chronic pancreatitis, a destructive fibroinflammatory disease of the
pancreas, can present with a variety of symptoms. There are several
causes of chronic pancreatitis, including toxic, obstructive, and
inherited, but all lead to progressive scarring and loss of pancreatic
function. Advanced fibrosis may lead to exocrine and endocrine
failure, resulting in abdominal pain, weight loss, nutritional deficien-
cies, and brittle diabetes. Chronic pancreatitis presents with non-
specific symptoms which can be mild; thus, the disease is significantly
under-diagnosed. The prevalence of chronic pancreatitis appears to
increase dramatically in the US and Europe during the past decade
[1–3]. This is an increasingly common disease in the population and
yet is difficult to diagnose yielding a very high cost per diagnosis ratio.
There is a limited understanding of the underlying molecular
events in chronic pancreatitis. It has previously been shown that
patients with chronic pancreatitis havean increased risk of developing
pancreatic cancer [4–7]; thus it is not surprising that many molecular
features presented in pancreatic cancer are also presented in chronic
pancreatitis [4–9]. Proteins are the essential biological molecules that
participate in numerous physiological functions; the changes at the
mRNA level may not always directly correlate to the changes at the
protein level [10]. Thus, further exploration of the pancreatitis
disease-specific protein expression profiles could 1) lead to better
diagnostic tests, 2) shed light on the mechanisms that underlie the
disease, and 3) provide information regarding the relationship of
chronic pancreatitis to pancreatic adenocarcinoma.
The emerging technology of quantitative proteomics provides a
powerful tool for the systematic identification of dysregulated
proteins associated with specific disease settings, and has been
widely applied to investigate an assortment of diseases, including
pancreatic cancer and pancreatitis [11–15]. Several studies have
reported tissue proteomics analysis on pancreatic carcinoma,
pancreatic intraepithelial neoplasia, and chronic pancreatitis,
providing new insights and hypotheses to further the understand-
ing of disease mechanism and biomarker development [8,16–23].
While most prior studies have used snap-frozen tissue specimens,
recently developed protein extraction techniques permit the use of
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analysis [24–29], providing a rich source of pathologically well-
characterized specimens for clinical proteomics study.
In this study, we investigate dysregulated proteins in early and
late stages of chronic pancreatitis, and compare them with the
proteins present in normal pancreas and pancreatic ductal
adenocarcinoma. The use of paraffin-embedded, formalin-fixed
materials provides the gold-standard for histologic analysis, which
in turn further optimizes proteomic correlation.
Methods
Patients and formalin-fixed paraffin-embedded
pancreatic tissue specimens
The formalin-fixed, paraffin-embedded pancreatic tissues from
pancreatic ductal adenocarcinoma and chronic pancreatitis
patients as well as normal healthy controls were obtained from
surgical specimens at the Cleveland Clinic with the approval of the
Cleveland Clinic Institutional Review Board and under HIPPA
compliant guidelines. The IRB approval was obtained with a
waiver of informed consent. Four study groups with five cases in
each group were included, including pancreatic ductal adenocar-
cinoma (PDAC), mild primary chronic pancreatitis (MCP), severe
primary chronic pancreatitis (SCP) and normal pancreas controls
(NL) (Table S1). The diagnoses for the patients and tissues used for
this study were confirmed by an experienced pancreatic
pathologist (co-author MPB), through the review of all current
and past histologic slides per patient, in addition to the blocks
selected for proteomic analysis. The diagnoses were further
confirmed by an experienced gastroenterologist specializing in
pancreatic disease (co-author TS). Representative pathologic
images from each of the four categories are shown in Figure 1.
The mild and severe pancreatitis diagnoses were assessed as
previously described [30] and based on the system proposed by
Ammann and colleagues [31]. Pancreatic parenchyma is com-
posed of grouped lobules of acini (functional units of the exocrine
pancreas) emptying into ducts. Chronic pancreatitis is quantified
according to the amount of intralobular and perilobular fibrosis
within the pancreatic parenchyma. The severity of fibrosis as mild,
moderate or severe and its distribution as focal or diffuse within
(intralobular) or surrounding (perilobular) tissue is quantified based
on a 0 to 12 point score [30,31]. Mild pancreatitis was defined by
scores of 1–4 and severe pancreatitis was defined by scores of 9–
12. For this proteomics study, scores in the moderate chronic
pancreatitis range of 5–8 were not used in an attempt to avoid
overlapping results. Diagnostic tissues were manually circled under
microscopic guidance by the pathologist (co-author MPB).
Pancreatic adenocarcinomas were selected to contain greater than
50% adenocarcinoma cells.
Extraction of proteins from paraffin-embedded tissue
Unstained 15 mm thick sections of formalin-fixed, paraffin-
embedded tissue were deparaffinized and rehydrated by heating to
60uC for 45 minutes, followed by a series of washes: xylene (twice,
5 minutes each), 100% ethanol (twice, 5 minutes each), 85%
ethanol (once, 3 minute), 70% ethanol (once, 3 minute), 50%
ethanol (once, 3 minute) and de-ionized water (once, 1 minute).
The corresponding H&E slides with the selected and circled
diagnostic areas of pancreatic adenocarcinoma, mild chronic
pancreatitis and severe chronic pancreatitis tissues were aligned
with the parallel tissue profiles on the prepared slides and were
manually microdissected. An equivalent of 1 cm61c m 615 mm
amount of deparaffinized tissue samples were scraped from each
slide and transferred into 300 ml lysis solution of 70% 50 mM
ammonium bicarbonate and 30% acetonitrile, using sterile blades
and needle tips. The lysates were then incubated at 90uC for
30 minutes followed by 60uC for 120 minutes to rehydrate the
proteins and hydrolyze crosslinks. The samples were sonicated for
2 minutes followed by 1 minute incubation on ice. The sonication
and ice incubation process was repeated twice more. The
homogenized samples were incubated at 60uC for 1 hr, followed
by the second sonication steps.
Sample preparation for proteomics analysis
The protein lysates were digested with sequencing-grade trypsin
(Promega, Madison, WI) at a trypsin to protein ratio of 1:50 at
37uC for 18 hours. The digested samples were centrifuged at
15006g for 10 minutes and the supernatants were collected. The
protein digests were reduced with 20 mM dithiothreitol (DTT) at
60uC for 60 minutes then incubated with 25 mM iodoacetamide
at room temperature in the dark for 30 minutes for cysteine
alkylation. The samples were then purified with C18 columns
(UltraMicroSpin Column/Vydac C18 silica, The Nest Group,
Inc., Southborough, MA), dried down and stored at 220uC until
mass spectrometric analysis.
LC MS/MS analysis
An LTQ-Orbitrap hybrid mass spectrometer (Thermo Fisher
Scientific, Waltham, MA) coupled with a nano-flow HPLC
(Eksigent Technologies, Dublin, CA) was used in this study. A
2 mg sample of each case was injected for the mass spectrometric
analysis. The samples were first loaded onto a 1.5 cm trap column
(IntegraFrit 100 mm, New Objective, Woburn, MA) packed with
Magic C18AQ resin (5 mm, 200 A ˚ particles; Michrom Biore-
sources, Auburn, CA) with Buffer A (water with 0.1% formic acid)
at a flow rate of 3 uL/minute. The peptide samples were then
separated by an 27 cm analytical column (PicoFrit 75 mm, New
Objective) packed with Magic C18AQ resin (5 mm, 100 A ˚
particles; Michrom Bioresources) followed by mass spectrometric
analysis. A 90-minute non-linear LC gradient was used as follows:
Figure 1. Histology of chronic pancreatitis, pancreatic adeno-
carcinoma and normal pancreas. a). non-disease pancreas; b). mild
chronic pancreatitis; c). severe chronic pancreatitis; d). pancreatic ductal
adenocarcinoma.
doi:10.1371/journal.pone.0027574.g001
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Buffer A over 2 minutes, then to 35% over 90 minutes, then to
50% over 1 minute, hold at 50% for 9 minutes, change to 95%
over 1 minute, hold at 95% for 5 minutes, drop to 5% over
1 minute and recondition at 5%. The flow rate for the peptide
separation was 300 nL/minute. For MS analysis, a spray voltage
of 2.25 kV was applied to the nanospray tip. The mass
spectrometry experiment was performed using data-dependent
acquisition with a m/z range of 400–1800, consisting of a full MS
scan in the Orbitrap followed by up to 5 MS/MS spectra
acquisitions in the linear ion trap using collision induced
dissociation (CID). Other mass spectrometer parameters include:
isolation width 2 m/z, target value 1e4, collision energy 35%, max
injection time 100 ms. Lower abundance peptide ions were
interrogated using dynamic exclusion (exclusion time 45 second,
exclusion mass width 20.55 m/z low to 1.55 m/z high). Charge
state screen was used, allowing for MS/MS of any ions with
identifiable charge states +2, +3, and +4 and higher.
Proteomics data analysis
The mass spectrometric data collected were processed using the
proteomics data processing pipeline recently described [32],
including the use of an Accurate Mass and Time (AMT) database
for peptide and protein identification and an ion intensity based
label-free approach for quantification.
Peptide and protein identification from tandem MS
data. Raw machine output files from all MS runs were con-
verted to mzXML files and searched with X!Tandem [33]
configured with the k-score scoring algorithm [34], against
version 3.69 of the human International Protein Index (IPI)
database. The search parameters were as follows: enzyme, trypsin;
maximum missed cleavages, 1; fixed modification, carbo-
xamidomethylation on cysteine; potential modification, oxidiza-
tion on methionine; parent monositopic mass error, 2.5 Da.
Peptide identifications were assigned probability by Peptide-
Prophet [35], and all identifications assigned probability ,0.95
(estimated false discovery rate: 0.006–0.007) were discarded. The
msInspect/AMT tools [36] were used to create an Accurate Mass
and Time (AMT) database containing all identified peptides that
were observed in at least two sample runs independently; these
filtration steps ensure that AMT matching occurs with a minimum
of background noise due to false identifications.
LC-MS feature detection, identification and peptide array
creation. The LC-MS peptide features in each run were located
by msInspect [37] using the default settings, and identified by
matching to the AMT database. Match probabilities were
calculated based on mass and RT error [38], and only matches
with probability $0.95 were retained. Feature intensities within
each sample run were normalized based on ion intensity
distribution as previously described [32,37,39] to eliminate the
effect of differences between machine runs. LC-MS data from the
two replicate runs of each sample were combined into a single
dataset per sample and assembled into a ‘‘peptide array’’ [37], in
which the rows represent the peptide features and the columns
describe peptide intensity. Features observed in only one replicate
were retained as-is; features observed in both replicates were
collapsed into a single feature and assigned the geometric mean
intensity of the two constituent features.
Peptide abundance comparison and protein ratio
quantification. All peptide identifications across the 5 sam-
ples of each disease group (PDAC, MCP and SCP) were assembled
into a single pepXML file [40] with a quantitative ‘‘ratio’’ (where
available) representing the ratio of geometric mean abundance in
the disease samples to the mean abundance of matching peptides
in the normal pancreas samples. Peptides observed in one of the
compared groups, but not the other, were assigned a ratio of 0 or
infinity accordingly, but were removed from the current analysis.
For each of the two group comparisons (PDAC:NL, MCP:NL and
SCP:NL) a t-test compared the peptide ion intensity ratio for each
peptide that was observed in at least two patient samples in each
group and generated a t-statistic. For each of the two group-
comparison pepXML files (PDAC:NL, MCP:NL and SCP:NL),
ProteinProphet [41] was used to infer the protein identifications
from the corresponding identified peptides. Protein ratios were
calculated using the geometric mean of all associated peptide
ratios. For each protein having two or more peptides with t-scores,
we performed an overrepresentation analysis, comparing the t-
statistics from all of the protein’s peptides with the t-statistics from
all other peptide t-statistics observed using a Wilcox test. The p-
values calculated from this analysis represented the probability of
observing the observed data if the protein was not differentially
abundant between groups. Finally, to correct for multiple testing
error, q-values [42] were calculated from those p-values.
Enrichment and pathway analysis
The enrichment analysis was performed using The Database for
Annotation, Visualization and Integrated Discovery (DAVID )
v6.7 [42]. The gene symbols of differential proteins were uploaded
for functional annotation analysis. Canonical pathway analysis was
performed using ingenuity pathways Analysis (Ingenuity Systems,
www.ingenuity.com). It identifies the pathways from the Ingenuity
Pathway Analysis library of canonical pathways that are most
significant to the data set. The whole data set were imported into
Ingenuity and 2-fold change was used as the cutoff value for
focusing on genes and/or proteins.
Immunohistochemical (IHC) analysis
All 20 cases that were used for proteomics analysis were
analyzed by IHC. Paraffin-embedded, formalin-fixed tissue blocks
were sectioned at 5 mm onto charged slides and deparaffinized,
processed for antigen retrieval in EDTA buffer (PH 8.0) and
microwaving for 18 minutes, followed by primary antibody
incubation at room temperature. The primary antibody dilutions
for lumican (Novusbio), versican (Sigma Aldrich), and collagen
alpha-1(XIV) chain (Sigma Aldrich) were 1:50, 1:200, and 1:5,
respectively. Biotinylated secondary antibody was used at 1:500
dilution and 3,39- Diaminobenzidine (DAB) was used as chroma-
gen.
Results
Proteomics pipeline and quantitative analysis
As schematically illustrated in Figure 2, the proteomics work-
flow for this study consists of two major components: extraction of
proteins from formalin-fixed paraffin-embedded tissue and a label-
free quantitative analytical pipeline [32] for identification and
quantification of proteins in diseased and control samples. Four
categories of tissue specimens were analyzed: mild chronic
pancreatitis (MCP), severe chronic pancreatitis (SCP), pancreatic
ductal adenocarcinoma (PDAC) and normal control (NL)
pancreatic tissue. In each group, 5 pathologically and clinically
well-characterized samples from each group were included for the
analysis. The unique peptide sequences identified by MS/MS
database search in each of the original 40 runs (duplicate analysis
on each samples) from all 20 samples with assigned probability
$0.95 by PeptideProphet were used to construct the AMT
database. The AMT database created from these runs contained
Proteomics Investigation of Chronic Pancreatitis
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e275743,360 unique peptides observed independently in at least two
different runs.
For each sample, LC-MS peptide ions were located and
assigned peptide identifications using AMT database matching,
and this information was combined across replicate sample runs.
The msInspect located an average of 18,974 ions per run; and
AMT matching identified an average of 1,620 of these ions per
run with probability $0.95, representing 1,484 unique peptides
per run. Sample replicate runs were combined; each sample
contained an average of 1,881 unique sequences with high-
probability AMT matches (range: 1,426–2,184).
Peptide identification and intensity information from all samples
were assembled into a single ‘‘peptide array’’ [32], and peptide
abundance ratios between the disease (MCP, SCP and PDAC) and
NL groups were calculated using the geometric mean peptide
intensity value from all samples in each group. The protein
identifications were inferred from peptide identifications. For
quantification, the ratio of a protein was obtained based on the
quantification of its corresponding peptides. Where possible, q-
values were calculated as described previously [32] for each
protein describing the probability of observing the observed
peptide information for that protein under the null hypothesis that
the protein was not differentially expressed. The proteomics
identification information is summarized in Table 1.
The samples were analyzed in a random order using the same
reversed-phase analytical column, LC gradient and instrument
parameters. To evaluate the technical reproducibility, all the 20
samples analyzed were combined to assess the correlation of
peptide intensity between two replicate runs. The ion intensity of
the peptides in each analysis were plotted versus each other. A
high average correlation (Spearman r=0.96) of the peptide
intensities between the replicates was observed (Figure S1),
indicating good technical reproducibility. It is of note that the
correlations of peptide ion intensity relationship and the protein
ratio relationship should not be compared directly since they
reflect very different measurement scales as previously discussed
[32]. At the protein level, the variation between replicates contains
the effects of variability from the entire analytic pipeline, including
Figure 2. The workflow of the label-free quantitative proteomics pipeline for analyzing dissected formalin-fixed, paraffin-
embedded tissue specimens.
doi:10.1371/journal.pone.0027574.g002
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peptide identification variability, as well as computational
variation that could vary from experiment to experiment (e.g.,
protein-level inference). Between the two replicate analyses, the
correlation coefficient (Spearman r) of the replicate protein log
ratio for MCP:NL, SCP:NL and PDAC:NL are 0.72, 0.88, and
0.96, respectively, as shown in Figure 3a. Further, for each
comparison, both replicate datasets are combined to obtain the
protein quantification data, providing additional improvement on
robustness for identifying the proteins that are differentially
associated with the diseases. The protein identification and
quantification information is provided in Table S2.
Differential proteins in mild pancreatitis, severe
pancreatitis and pancreatic adenocarcinoma
The comparative analysis between the disease groups and the
normal control group was achieved using AMT and intensity based
label-free approach as described above. To evaluate the variations
within a group, the distribution of coefficient of variance (CV) of
intensities of each peptide that were detected in at least two samples
in each group is provided in Figure S2. For NL, MCP, SCP and
PDAC, the medians are 0.36, 0.40, 0.35 and 0.37, respectively; and
there is a trend toward tighter CVs as intensity increases. Figure 3b
shows the distribution of protein ratios in MCP:NL, SCP:NL and
PDAC:NL. The proteins with a 2-fold or more change in diseases
states (MCP, SCP or PDAC) versus NL are listed in Table S3. The
number of the differential proteins with 2-fold or more abundant
change in MCP, SCP and PDAC increased substantially as the
disease severity increases, from 87 to 217 and to 298, respectively
(Figure 4a). Further examination of the differential proteins
indicated that some of the proteins are concurrently expressed in
two or all disease categories. Figure 4b shows the comparison of the
differential proteins with concurrent abundance change between
each category. There are significant portions of differential proteins
in MCP (51 proteins, 58%) and SCP (138 proteins, 63%) that are
concurrently expressed in PDAC, consistent with our previous
study [8]. Not surprisingly, the majority of the differential proteins
in MCP (66 proteins, 75%) are concurrently expressed in SCP.
Among these proteins, 15 proteins are exclusively expressed in both
MCP and SCP, but not in PDAC (Table S3). Our current study has
expanded our previous discovery and confirmed many of the
differential proteins that were previously identified in pancreatic
adenocarcinoma, PanIN and chronic pancreatitis from our
previous proteomic studies using snap frozen tissues, [8,17,22] as
indicated in Table S3.
Functional clustering of differential proteins
Further analysis of the differential proteins in each category
using the DAVID bioinformatics software [42] reveals the
enriched biologic clusters in each disease group. For the over-
expressed proteins in all 3 disease categories (MCP, SCP and
PDAC), the most significant biological processes involved are
extracellular matrix organization and structure organization. In
addition to that, in SCP the functional enrichment analysis reveals
the up-regulation of biological processes related to cell adhesion
(23 proteins), response to wounding (28 proteins) and defense
response (25 proteins), two processes that are fundamental to the
pathogenesis of inflammation. In comparison, significant enrich-
ment of inflammatory related processes is not observed in MCP, in
which collagen fibril organization (7 proteins) is the main process
that is up-regulated. In PDAC, the enrichment of up-regulation of
actin filament-based process (16 proteins), cytoskeleton organiza-
tion (19 proteins) and response to wounding (25 proteins) is
observed.
A proteomics view of pathophysiologic abnormalities of
pancreas associated with chronic pancreatitis
Acinar cell secretory and related proteins – digestive
enzymes and inhibitors. Among the differential proteins
identified, we observe a decrease in abundance across several
enzymes that are secreted by pancreas acinar cells in SCP and
PDAC compared to normal controls. These digestive enzymes
include proteases, amylolytic enzymes and lipases, such as trypsin-1
(PRSS1), chymotrypsins (CTRC, CTRL, CTRB2), phospholipase
A2 (PLA2G1B), ectonucleotide pyrophosphatase (ENPP1), carbo-
xypeptidases (chronic pancreatitisA1, chronic pancreatitisA2,
chronic pancreatitisB1), chymotrypsin-liked elastases (CELA2A,
CELA2B, CELA3A), pancreatic triacylglycerol lipase (PnormalIP),
pancreatic lipase-related protein 2 (PnormalIPRP2) and carboxyl
ester lipase (CEL). The abundance changes of these proteins are
illustrated in Figure 5. Using 0.5 as an abundance ratio cut-off,
many of these enzymes are down-regulated (,0.5 fold) in SCP and
PDAC, but have less significant changes in MCP. Another interest-
ing group of proteins that are related to acinar cells are protease
inhibitors. This group of proteins, including trypsin inhibitor
(SERPINA1, ITIH1), chymotrypsin inhibitor (SERPINA3), plasma
protease C1 inhibitor (SERPING1) and ribonuclease inhibitor
(RNH1), all elevate significantly in the pancreatic tissue of MCP,
SCP and PDAC (Figure 5), implying a possible involvement of
protective mechanisms in the disease states.
Differential proteins associated with pancreatic fibro-
sis. Fibrosis is one of the fundamental histological abnormalities
observed in chronic pancreatitis and pancreatic adenocarcinoma.
One of the most enriched groups of the over-expressed proteins in
MCP, SCP and PDAC includes those involved in extracellular
matrix (ECM) structure and organization, which regulates fibrosis.
Figure 6 shows the relative abundance change of some of the
differential proteins that are related to ECM and stellate cell
activation. Some of these proteins, for example, periostin (POSTN),
are involved in cell mobility and neovascularization for promoting
angiogenesis [43]. In SCP and PDAC, most of these proteins show
more than 2-fold change in abundance compared to normal tissue.
Some of these proteins are also over-expressed (.2-fold) in MCP,
including fibrillin-1 (FBN1), a group of collagens (COL14A1,
Table 1. Summary of proteomics identification in comparison of MCP to NL, SCP to NL and PDAC to NL.
Comparison groups
Protein
identification
Quantified
proteins
Peptides used for t-statistics
(observed in $2 samples/group)
Proteins with
q-value calculated
Mild chronic pancreatitis:Normal 924 799 2010 378
Severe chronic pancreatitis:Normal 953 755 1702 340
Pancreatic adenocarcinoma:Normal 996 697 1403 290
doi:10.1371/journal.pone.0027574.t001
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COL6A3), transgelin (TAGLN), transforming growth factor-beta-
induced protein IG-H3 (TGFBI), lumican (LUM), utrophin
(UTRN), decorin (DCN), emilin-1 (EMILIN1), myosin-11
(MYH11) and dermatopontin (DPT). As observed in Figure 6,
many of these proteins similarly increase in abundance in chronic
pancreatitis and pancreatic adenocarcinoma. However, their
specific roles involving in the two different disease mechanisms
remain to be defined.
Glycoproteins. Membrane proteins and secreted proteins
are frequently glycoproteins. In addition, glycoproteins are
important components of the ECM. Collagen, proteoglycans
and other ECM specialized glycoproteins such as fibrillin,
fibronectin and laminin all contain various degrees of
glycosylation [44]. In our study, glycoproteins, especially those
with N-linked glycosylation sites, are significantly enriched among
the over-expressed proteins in MCP (40%), SCP (45%) and PDAC
(40%). These glycoproteins are indicated in Table S3.
Inflammatory proteins. Inflammatory proteins and pro-
teins that respond to wounding are particular enriched among the
over-expressed proteins in SCP (28 proteins) and PDAC (25
proteins). As shown in Figure 7, many of these proteins were
elevated more than 2-fold in abundance in SCP and PDAC
compared to controls, but less so for MCP. In addition, a group of
Figure 3. Quantitative proteomics results. a). evaluation of the reproducibility between the duplicates at protein level; b). histogram of protein
ratio distribution in natural log scale.
doi:10.1371/journal.pone.0027574.g003
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inflammation, tissue remodeling and reorganization, are over-
expressed in SCP and PDAC. It is of note that some classic
inflammatory markers such as TNF alpha, IFN gamma, IL-6, IL-8
were not directly detected in our samples, probably due to the low
abundance of these cytokines in the pancreas tissue.
IHC analysis of lumican, versican and Col14A1
Three up-regulated proteins were confirmed using immunohis-
tochemistry (IHC), as shown in Figure 8. These proteins were
selected based on: 1) their high ratio in diseases versus normal; 2)
their $2 ratio of SCP/MCP. Lumican (LUM), a proteoglycan that
interacts with collagen and helps define the extracellular matrix
architecture is strongly over-expressed in MCP, SCP and PDAC
by 6.3 fold, 12.8 fold and 13.0 fold respectively by proteomics
analysis. The up-regulation of lumican (Figure 8a–d) is detected in
the acinar cells of chronic pancreatitis (both MCP and SCP) and
PDAC. In addition, expression of lumican is increased in the
extracellular matrix (ECM) of SCP and PDAC, but only mildly
increased in MCP. Versican is a proteoglycan in the ECM that
mediates cell proliferation, adhesion and migration. It is strongly
over-expressed in SCP and PDAC by 8.2 fold and 20.7 fold
respectively by proteomic analysis. Using IHC to identify the
affected cell type in tissue sections, we found that versican is
markedly increased in the ECM of SCP and PDAC (Figure 8e–h)
and to a lesser extent in MCP compared to normal pancreas. In
addition, increased expression of versican is observed in the acinar
cells of MCP and SCP. Another ECM glycoprotein, collagen
alpha-1(XIV) chain (Col14A1), is increased in MCP, SCP, and
PDAC by 6.9, 16.4 and 11.4 fold respectively, by proteomics
analysis. Consistent with the proteomic results, in IHC, Col14A1 is
highly expressed in both the epithelial cells and acinar cells of
MCP and SCP (Figure 8i–l). Although Col14A1 is a secreted
protein, surprisingly, there is no staining of this protein in the
ECM of chronic pancreatitis and pancreatic adenocarcinoma.
One possible explanation could be that the Col14A1 protein
undergoes further modification when secreted or is lost in the
processes of tissue fixation of the IHC protocol.
Canonical pathway analysis
Ingenuity Pathways Analysis was used to further explore the
well-defined canonical pathways involved in MCP, SCP and
PDAC. The top three canonical pathways up-regulated in MCP,
include (1) pancreatic fibrosis/pancreatic stellate cell activation
(p=2.05E-04); (2) intrinsic prothrombin activation (p=2.98E-04);
and (3) acute phase response signaling (p=7.15E-04). The top
three canonical pathways in SCP were (1) acute phase response
signaling (p=4.59E-13); (2) intrinsic prothrombin activation
pathway (p=3.97E-08); and (3) extrinsic prothrombin activation
pathway (p=3.17E-05). Although the pancreatic fibrosis/stellate
cell activation pathway was not ranked in the top three pathways
in SCP, all of the 5 proteins involved in this pathway in MCP were
also up-regulated in SCP. Comparing to MCP, acute phase
response signaling is more prominent in SCP with 18 up-regulated
proteins involved in this pathway. In contrast, only 5 proteins in
this pathway were up-regulated in mild chronic pancreatitis. In
PDAC, the top three canonical pathways were (1) citrate cycle
(p=1.17E-08), (2) propanoate metabolism (p=5.82E-08), and (3)
acute phase response signaling (p=3.06E-07). Two of these
pathways were related to metabolism, which is different from the
top pathways in MCP and SCP.
Discussion
The molecular events underlying the pathogenesis of chronic
pancreatitis remains an area of great interest and uncertainty. In
addition, the relationship between chronic pancreatitis, a known
risk factor for pancreatic adenocarcinoma is a model system to
studying the paradigm of how chronic inflammation leads to
neoplastic progression. Here, we present a quantitative global
proteomics study to investigate the tissue proteome alterations
associated with mild and severe chronic pancreatitis and compare
those findings to the proteomic profiles of normal pancreas and
pancreatic cancer. The development of protein extraction
techniques for fixed tissues opens a new avenue for clinical
proteomics study by providing a rich source of pathologically well-
characterized specimens. Using clinically well-defined formalin-
fixed, paraffin-embedded pancreatic tissues, we have uncovered
the concerted molecular activities and pathways that correlate with
histological inflammation and fibrosis.
Figure 4. The differentially expressed proteins in MCP, SCP and
PDAC. a). the number of differential proteins in MCP, SCP and PDAC
using normal pancreas as a comparison. b). the overlap of the
differential proteins with concurrent abundant changes in MCP, SCP
and PDAC.
doi:10.1371/journal.pone.0027574.g004
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27574Figure 5. The expression of pancreatic acinar cell secretory enzymes and the related inhibitors.
doi:10.1371/journal.pone.0027574.g005
Figure 6. The expression of some of the differential proteins related to ECM and stellate cell activation.
doi:10.1371/journal.pone.0027574.g006
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allows the identification of differential proteins that are not only
presented in ductal cells or acinar cells but also in the host
microenvironment, reflecting a more complete picture of what
could be underlying the pathogenesis of chronic pancreatitis. We
chose a label-free pipeline to analyze the formalin-fixed, paraffin-
embedded samples using high resolution Orbitrap mass spectrom-
eter. The comparison of the replicates at both peptide and protein
level indicates that the label-free pipeline is adequate for
quantitative proteomics analysis in this study to identify systematic
differences in protein profiles across experimental conditions.
Both chronic pancreatitis and pancreatic adenocarcinoma cause
damage to the pancreas, including chronic inflammation, fibrosis,
and progressive destruction of both exocrine and eventually
endocrine tissue [45]. While some of these parenchymal changes
can be observed histologically, the disease and its progression may
induce a more profound disturbance at the molecular level. At the
proteome level, we have previously found some commonality of
dysregulated proteins that are shared between chronic pancreatitis
and pancreatic adenocarcinoma [8]. These observations are
expanded in the current study.
Using normal pancreatic tissue as a comparison, the number of
differential proteins increases substantially from mild to severe
chronic pancreatitis, and even more in pancreatic adenocarcino-
ma, possibly reflecting the changes in the proteome of pancreatic
tissue with progressive severity and/or complexity. Further
analysis of the differential proteins (discussed below) implied that
such changes in pancreas tissue proteome might be in part
associated with the changes in acinar cell abundance and
increased level of fibrosis in MCP, SCP, and PDAC, as observed
in histology. In addition, the presence of cancerous cells in PDAC
might induce additional proteome perturbations comparing to
normal pancreas and chronic pancreatitis. The significant overlap
of the differential proteins between chronic pancreatitis and
pancreatic adenocarcinoma suggests that chronic pancreatitis and
pancreatic adenocarcinoma share many molecular features at the
protein level. Alternatively they may reflect that most pancreatic
adenocarcinoma patients also have chronic pancreatitis as either a
primary or secondary process.
Functional clustering analysis of the differential proteins revealed
that extracellular matrix organization is the most significant and
common biological process among chronic pancreatitis and
pancreatic adenocarcinoma. In addition, for SCP, a significant
up-regulation of proteins associated with cell adhesion, response to
wounding and defense response was observed. As a comparison, the
significant up-regulated proteins observed in PDAC include those
that play a role in actin filament-based processes, cytoskeleton
organization and response to wounding. Actin filaments are a major
component of the cytoskeleton. In addition to its functions in
structural framework for cell shape and motile events, recent studies
has shown that the cytoskeleton also plays critical roles in the
regulation of various cellular processes relating to proliferation,
contact inhibition, anchorage-independent cell growth, and apop-
tosis [46]. Indeed, cytoskeleton remodeling is an important process
in cancer invasion and metastasis. It is not surprising that the
proteins relating to the cytoskeleton are enriched in the pancreatic
adenocarcinomatissue.Responsetowoundingwasenrichedinboth
severe chronic pancreatitis and pancreatic adenocarcinoma. The
enrichment of proteins involved in wounding response in SCP is
consistent with the complex molecular events occurring in wound
healing, including proliferation of fibroblasts, accumulation of
EMC, and release of matrix metalloproteinases, growth factors and
cytokines. The finding of enriched proteins related to the wounding
response is not surprising in pancreatic cancer: it has long been
known that tumors are like wounded tissues that do not heal.
The proteomic data evidenced that digestive enzymes were
significantly decreased in SCP and PDAC tissue lesions. While the
increase of pancreatic enzymes in blood, such as amylase and
lipase, may be a signal of acute pancreatic injury, the significant
reduction of enzymes that are secreted from acinar cells in chronic
pancreatitis tissue may reflect the possible destruction and loss of
acinar cell mass. The fact that amylase and lipase are generally not
elevated in the blood of patients with chronic pancreatitis or
pancreatic cancer would clinically fit with the proteomic findings
Figure 7. The expression of some of the differential proteins associated with wounding response and inflammation.
doi:10.1371/journal.pone.0027574.g007
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activation of trypsinogen contributes to pancreatitis and is, in part,
mediated by the activity of cathepsin B (CTSB) [47]. Indeed, the
abundance of this protein is associated with the severity of
pancreatitis, significantly over-expressed (.2-fold) in SCP and
PDAC, but not in MCP compared to normal pancreas. It is also
important to note that while most of the digestive enzymes were
down-regulated in severe chronic pancreatitis and pancreatic
adenocarconoma, tryptase (TPSAB1) was up-regaulated in
chronic pancreatitis and adenocarinoma (Table S3). Tryptase is
the most abundant serine protease selectively concentrated in the
secretory granules of mast cells [48] – an inflammatory cell that
also involves in chronic pancreatitis [49]. The up-regulation of
tryptase is consistent with a previous observation at gene level
using DNA arrays [50], and may imply the increase of mast cells in
chronic pancreatitis and adenocainoma.
On the other hand, enzyme inhibitors are up-regulated in these
conditions, potentially reflecting protective mechanisms associated
with severe chronic pancreatitis and carcinoma. It may be worthy
of mentioning that a well-studied protease inhibitor, pancreatic
secretory trypsin inhibitor (Serine protease inhibitor Kazal-type 1,
SPINK1), whose gene mutation was frequently associated with
chronic pancreatitis and pancreatic adenocarcinoma by a number
of studies [51,52], was not detected in any pancreatic tissue in our
current investigation. However, this protein was indeed found up-
regulated in the pancreatic juice [53] and plasma [54] of
pancreatic cancer patients in our previous studies.
A significant number of proteins that are involved in the ECM
structure and organization were observed up-regulated in chronic
pancreatitis and pancreatic adenocarcinoma. It is known that
persistent activation of pancreatic stellate cells that secret ECM
promotes fibrosis [55]. Thus, the proteomic results are well
Figure 8. Immunohistochemical confirmation of proteomic findings in chronic pancreatitis and pancreatic adenocarcinoma.
Lumican (a–d) not seen in NL (a), but is overexpressed in acinar cells of MCP (b), SCP (c), and only in the stroma of PDAC (d). Versican (e–h) is mainly
over-expressed in the stroma of MCP (f), SCP (g), and PDAC (h). Col14A1 (i–l) is over-expressed in acinar and ductal cells of MCP (j), and SCP (k), but
not in PDAC (l).
doi:10.1371/journal.pone.0027574.g008
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promoted by pancreatic stellate cell activation. As an important
component of ECM, a large number of glycoproteins were
observed up-regulated in mild and severe chronic pancreatitis as
well as pancreatic adenocarcinoma, implicating their role in the
ECM changes that occur in these diseases and the possible
pathologic implication of glycosylation. The increase in proteins
associated with ECM and stellate cell activation and the presence
of a large number of up-regulated tissue glycoproteins supports the
concept that pancreatic fibrosis occurs in mild and severe chronic
pancreatitis and cancer.
Proteins involved in wounding response and inflammation are
also over-expressed in SCP and PDAC. Canonical pathway
analysis also indicated that the acute phase response signaling
pathway was ranked as a top canonical pathway in MCP, SCP and
PDAC, suggesting the importance of this pathway in these disease
processes. In addition, prothrombin activation pathway, and
pancreatic fibrosis/pancreatic stellate cell activation pathway were
the most significant pathways involved in chronic pancreatitis,
while pathways relating to metabolism were the most significant
pathway in pancreatic adenocarcinoma.
Thrombosis has long been observed as a common complication
in chronic pancreatitis [56,57], resulted from inflammatory,
pseudocysts, pancreatic fibrosis and other factors. The observation
of remarkable prothrombin activation in SCP may imply a
possible cyclical injury process, causing further damage to the
vessels that perfuse the tissue as disease progresses, if further
validated. On the other hand, antithrombin III – an inhibitor of
thrombin, was 2-fold increased in SCP, probably suggesting a
negative feedback mechanism.
The IHC analysis of lumican, versican and Col14A1 confirmed
their up-regulation in chronic pancreatitis and pancreatic
adenocarcinoma, and provided additional insights on how they
behave at cellular level in association with the diseases. It is of note
that previous studies also observed the strong presence of lumican
and versican in cancer cells [58,59]. Lumican plays a pivotal role
in cell migration and proliferation, is localized in alpha cells of
islets and stromal tissues of a normal pancreas. The synthesis of
this protein by cancer cell may suggest its role in pancreatic
adenocarcinoma cell growth, in addition to the inflammatory
process. Other studies of lumican in pancreatic adenocarcinoma
suggests an increased risk for invasion and poor prognosis for
patients who have strong staining in the cancer-associated stromal
cells [60].
While the biological implication for many of the dysregulated
proteins discovered in this study still remains unclear and warrants
further investigation to unravel their role in the pathogenesis of
chronic pancreatitis and pancreatic cancer, our work has revealed
new molecular insights and hypothesis for better understanding
mechanisms that underlie pancreatitis and pancreatic adenocar-
cinoma. Moreover, the differential proteins identified could serve
as potential candidates for biomarker development to improve the
diagnosis and treatment of pancreatic diseases.
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